We confirmed that Bortezomib, similar to experimental tool agent thapsigargin, induced the ER stress in ErbB2-overexpressing breast cancer cell lines and that CHIP KD cells exhibited higher sensitivity to thapsigargin or Bortezomib (Figure 4D). The gene discussed is STUB1; the disease is breast carcinoma.